COMPARATIVE EVALUATION OF SELECTED POLYMERS AND PLASTICIZER ON TRANSDERMAL DRUG DELIVERY SYSTEM by Sethi, Bhawana & Mazumder, Rupa
 
 
COMPARATIVE EVALUATION OF SELECTED POLYMERS AND PLASTICIZER ON 
TRANSDERMAL DRUG DELIVERY SYSTEM 
Original Article 
 
BHAWANA SETHI1, RUPA MAZUMDER2 
1Innovative College of Pharmacy, Greater Noida, Uttar Pradesh 201308, India, 2
Received: 10 Aug 2017, Revised and Accepted: 28 Nov 2017 
Noida Institute of Engineering and Technology, Greater 
Noida, Uttar Pradesh 201308, India 
Email: sethimpharma@gmail.com   
ABSTRACT 
Objective: The present work was aimed at preparation of transdermal patches by a solvent casting method using a varying concentration of polymers 
i.e. methocel (K15 and K100), ethocel (4 and 10), gelatin, chitosan, eudragit (RL and RS) grade using plasticizer (glycerin and propylene glycol). 
Methods: The ratio of drug to polymers and plasticizer was varied and the effect of formulation variables was studied. Prepared transdermal patches 
were evaluated for physicochemical properties, in-vitro permeation studies, content uniformity, primary skin irritation studies and FT-IR studies. 
Results: The formulated transdermal patch by using Methocel K 100 M showed good physical properties. The average weight of patches prepared 
using glycerin as a plasticizer were ranged from 42.33-67.00 mg and propylene glycol as a plasticizer were ranged from 40.67-67.67 mg. The 
percentage moisture absorption varies from 1.76 to 10.73 for patches formulated using glycerin and 2.28 to 7.97 for propylene glycol patches. The 
percentage moisture loss from patches prepared using glycerin was ranged from 2.75 to 11.54 and 2.87 to 12.02 from propylene glycol. The water 
vapour transmission rate from patches prepared using glycerin was ranged from 0.25 to 0.92 and 0.41 to 1.76. The formulated patch showed the 
acceptable quantity of medicament ranged from (100.20-101.05%). This result met the test content uniformity as per BP (85% to 115%). According 
to that, the drug was consistent throughout the patches. The formulation PGD is considered as the best formulation, since it shows a maximum in 
vitro drug release as 43.75 % at 24 h. The drug release kinetics studied showed that the majority of formulations was following zero order. 
Conclusion: In conclusion, controlled release transdermal drug delivery system patches of aliskiren can be prepared using polymer combinations, 
with a different plasticizer. The release rate of drug depends upon the polymer. However, release kinetics followed zero order. 
Keywords: Transdermal Patches, Aliskiren Hemifumarate, Methocel (K15 and K100), Ethocel (4 and 10), Gelatin, Chitosan, Eudragit (RL and RS), 
Glycerin, Propylene glycol, Solvent casting method, Hypertension 




In the current scenario, hypertension is the major factor for 
cardiovascular disease and the leading cause of death in economically 
developed countries. The renin-angiotensin system (RAS) is the main 
regulator of blood pressure and body fluid volume and acts primarily 
via the effects of the octapeptide hormone, angiotensin II (AngII). Ang 
II is formed in a two-step: angiotensinogen converted to angiotensin I 
(AngI), which is then converted by angiotensin converting enzyme 
(ACE) into AngII. Ang II increases blood pressure and exerts direct 
growth-promoting effects on cardiac and renal tissue that causes 
organ damage [1-3]. Renin inhibitors avoid the formation of AngI and 
AngII and so may act differently from arbs, which increase angiotensin 
peptide levels, and ACE inhibitors, which increase AngI levels and do 
not block ace-independent AngII production [4-7]. 
From past few years, topical delivery for treatment of hypertension 
shows better results. The barrier causing agent during transdermal 
delivery is “Skin”. Skin plays a vital role for the transportation of the 
drug. There are three routes from which molecules can penetrate 
the skin: (1) intracellular, (2) intercellular lipids, and (3) 
appendages. Absorption through the skin is affected by a number of 
factors including the origin (human, animal), type of skin, 
physicochemical properties of the compound and formulations, as 
well as possible skin pretreatment and environmental factors [6-9]. 
Major advantages of transdermal drug delivery: the constant level of 
drug is maintained within the therapeutic window during the whole 
period of the administration; the pre-systemic first-pass effect can 
be avoided which can result in higher bioavailability and fewer 
adverse effects than in the case of oral administration; the drug 
administration can be stopped instantly in situations where drug 
input is no longer desirable; it allows a reduced frequency of dosing 
which is particularly favourable for compounds with short biological 
half-life [10-14]. 
The ideal properties of a molecule penetrating intact stratum 
corneum (sc) well are: Molecular mass less than 600 Da, when the 
diffusion coefficient in sc tends to be high, Log P value between 1 
and 3, High, but balanced, sc/vehicle partition coefficient, such that 
the drug can diffuse out of the vehicle, partition into, and move 
across, the sc without becoming sequestered within it [6, 9]. 
Aliskiren hemifumarate is selected for the treatment of hypertension 
because it rapidly absorbed through oral administration, with a low 
bioavailability ~2.6%. The terminal half-life ranges between 23 to 36 
h. Aliskiren is eliminated primarily as unchanged drug in the feces; less 
than 1% was excreted in the urine. Aliskiren is a hydrophilic molecule 
(log Poct=water 2.45 at pH 7.4) with favourable physicochemical 
properties including high aqueous solubility (>350 mg/ml at pH 7.4) 
that were considered an important prerequisite for improved oral 
bioavailability. Aliskiren has as its free base (pKa = 9.49) the molecular 
formula C30H53N3O6
MATERIALS AND METHODS 
 and a molecular mass of 609.8 g/molas hemi 
fumarate salt [1, 15, 16]. The aim of the study was to reduce the dosing 
frequency, increase the bioavailability of the drug by novel drug 
delivery over conventional formulation. 
Materials 
Gift sample of aliskiren hemifumarate was provided by dr. morepen, 
methocel and ethocel from colorcon Mumbai. All other 
reagents/solvents used in this study are of analytical grade (sigma 
aldrich). Transdermal films containing aliskiren hemifumarate were 
prepared by solvent casting technique using mercury as a substrate. 
Overall forty-eight formulations were formulated using a different 
type of polymer in varying ratio and different plasticizer [17]. 
The animal used for skin irritation studies were adult rats weighing 
from 200-220 g, from the animal house of Innovative College of 
pharmacy, Greater noida. The experiment was conducted out in the 
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facility having an approved animal house (1346/c/10/CPCSEA). The 
animals were housed in polypropylene cages, 4 per cage with free 
acess to water and standard laboratory diet (Lipton feed, Mumbai, 
India). They were kept at 25±1 °C and 45-55% relative humidity 
with a 12h light/dark cycle. No rats were harmed during the study 
and after completion of the experiment, rats were housed. 
Experimental methods 
Preparation of transdermal patches 
Transdermal patches containing aliskiren hemifumarate were 
prepared by a solvent casting method. As shown in table 1, casting 
solutions were prepared by dissolving appropriate ratio of polymer, 
the plasticizer in a suitable solvent using magnetic stirrer. The 
mixture was stirred continuously in such a manner that evaporation 
of the solvent was minimized. The drug was added slowly to the 
solution and dissolved by continuously stirring for 30 min. 
Casting of matrices 
For the formulation of films, mercury was spread uniformly on a 
glass petridish. The glass mould was kept on a mercury surface. 
About 5 ml of the solution was poured on the mercury. The rate of 
evaporation was controlled by inverting the funnel over the mould. 
After 6-7 h, the dried patches were removed from the mould and 
wrapped in aluminum foil and stored over fused calcium chloride in 
a desiccator at room temperature for further use. 
 
Table 1: Composition of transdermal patches using glycerin and propylene glycol as plasticizer 
S. No. Formulation Code Composition @ 
(Drug: polymer) 




* (% w/w)* 
1 Methocel K 15 M A 1:1 150 150 Chloroform: Dichloromethane: Ethanol 
2 Methocel K 15 M B 1:1.5 150 150 --- 
3 Methocel K 15 M C 1:2 150 150 --- 
4 Methocel K 100 M D 1:1 150 150 --- 
5 Methocel K 100 M E 1:1.5 150 150 --- 
6 Methocel K 100 M F 1:2 150 150 --- 
7 Ethocel Standard  G 1:1 150 150 Chloroform 
8 Ethocel Standard 4 H 1:1.5 150 150 Chloroform 
9 Ethocel Standard 4 I 1:2 150 150 Chloroform 
10 Ethocel Standard 10 J 1:1 150 150 Chloroform 
11 Ethocel Standard 10 K 1:1.5 150 150 Chloroform 
12 Ethocel Standard 10 L 1:2 150 150 Chloroform 
13 Chitosan M 1:1 150 150 Water 
14 Chitosan N 1:1.5 150 150 Water 
15 Chitosan O 1:2 150 150 Water 
16 Gelatin P 1:1 150 150 Water 
17 Gelatin Q 1:1.5 150 150 Water 
18 Gelatin R 1:2 150 150 Water 
19 Eudragit RL S 1:1 150 150 Acetone 
20 Eudragit RL T 1:1.5 150 150 Acetone 
21 Eudragit RL U 1:2 150 150 Acetone 
22 Eudragit RS V 1:1 150 150 Acetone 
23 Eudragit RS W 1:1.5 150 150 Acetone 
24 Eudragit RS X 1:2 150 150 Acetone 
*% w/w of the polymer, @
 
formulation code for propylene glycol: PG used as a prefix before code. 
Compatibility studies of drug and polymers  
The Fourier transform infrared (Perkin Elmer IR spectrometer 4000-
400 Vmax in cm-1) analysis was the most powerful technique for 
qualitative compound identification. The main application of Fourier 
transform infrared spectrophotometry was a determination of the 
identity of a compound by means of spectral comparison with that of a 
reference and verification of the presence of functional groups in an 
unknown molecule. The potassium bromide pellet of the drug was 
prepared by grinding 3-5 mg of the sample with 100-150 mg of 
potassium bromide in pressure compression machine. The sample 
pellet was mounted in fourier transform infrared compartment and 
scanned between at wavelength 4000 cm-1-400 cm-1
Evaluation of transdermal patches 
. The principal 
peaks of pure aliskiren hemifumarate and the selected polymers were 
evaluated. The resulted values show that the peaks don't-shift 
significantly in the fourier transform infrared spectra. The comparison 
with the pure drug as seen in fig. 1 and 2, respectively, indicating the 
compatibility of the drug with the polymers used. 
The patches were evaluated for the following physicochemical 
properties. 
Weight variation 
Uniformity of weight was determined by weighing three matrices of each 
formulation. After each film unit was weighed individually on a digital 
balance, the average weight of film was taken as the weight of the film.  
Percentage moisture absorption 
The films were weighed accurately and placed in the desiccator 
containing 100 ml of saturated solution of aluminium chloride, 
which maintains 79.50% RH. After 3 d, the films were taken out and 
weighed. The percentage moisture absorption was calculated using 
the formula.  
Percentage moisture absorption =  
 
Percentage moisture loss 
The films were weighed accurately and kept in a desiccator 
containing anhydrous calcium chloride. After 3 d, the films were 
taken out and weighed. The moisture loss was calculated using the 
formula. 
Percentage moisture loss =  
 
Water vapour transmission rate 
Glass vials of equal diameter were used as transmission cells. These 
transmission cells were washed thoroughly and dried in an oven. 
About 1 g anhydrous calcium chloride was placed in the cells and the 
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respective polymer film was fixed over the brim. The cells were 
accurately weighed and kept in a closed dessicator containing a 
saturated solution of potassium chloride to maintain a humidity of 
84%. The cells were taken out and weighed after 6, 12, 24, 36, 48, 
and, 72 h of storage. The amount of water vapour transmitted was 
calculated using the formula.  
Water vapour transmission rate =  
 
Thickness 
The thickness of the patch was measured at five different points 
using a screw gauge (Mitutoyo Japan) and average thickness 
recorded. 
Content uniformity 
A film was cut into small pieces and put in 100 ml buffer (pH 7.4). 
This was shaken on a mechanical shaker for 2 h to get a 
homogeneous solution and filtered. The resulting solutions were 
quantitatively transferred to volumetric flasks, and appropriate 
dilutions were made with pH 7.4 Phosphate buffer. The resulting 
solutions were filtered and analyzed for drug content at 279 nm in 
UV spectrophotometer. The average reading of three patches was 
taken as the content of drug in one patch.  
In vitro permeation study 
For the study of in vitro release patterns from the prepared TDDS 
formulation, a franz diffusion cell was used. The films were placed in 
between the donor and donor-receptor compartment in such a way 
that the drug releasing surface faced toward the receptor 
compartment. The receptor compartment was filled with phosphate 
buffer and stirred with magnetic bead and the temperature was 
controlled at 37±1 °C.  
A sample of 5 ml was withdrawn at predetermined intervals, being 
replenished by equal volumes of the elution medium. This was carried 
out for a period of 24 h. The drug concentration in the aliquot was 
determined and calculated and shown graphically from fig. 3 to 6. 
Primary skin irritation studies 
The mice were divided into 4 groups (n=6). On the previous day of 
the experiment, the hair on the back-side area of mice was removed. 
The animal of group I served as normal, without any treatment. 
Group II of animals was applied with marketed adhesive tape 
(official adhesive tape in USP). Transdermal systems (blank, without 
drug and drug loaded) were applied onto the nude skin of animals of 
group III and IV. The application sites were graded according to 
visual scoring scale, always by the same investigator. The erythema 
scale was as follows: 0, none; 1, slight; 2, well defined; 3, moderate 
and 4, severe 
The patches were tested for their potential to cause skin 
irritation/sensitization in healthy albino rats of 200-220 gms. The 
skin from the back of each rat was depilated 24 h prior to the 
application of the patch.  
The skin was cleared with rectified spirit. The patches were placed 
over the skin with the help of adhesive tape. They were removed 
after 24 h exposure. Upon removal of patches, the resulting reaction 
was evaluated according to US-FDA grading scale. [17-20]. 
RESULTS AND DISCUSSION 
FTIR studies 
The infrared spectral analysis of aliskiren hemifumarate alone 
showed that, the principle peaks were observed at wave numbers of 
2932.66, 2969.47, 2875.29 cm−1, that can be attributed to the 
asymmetric C-H stretching vibration of drug and also the 
characteristic bands at 1306.24 cm−1, 1425.59 cm−1, 1445.15 cm−1 
and 1515.86 cm−1, due to as (C-O). The two bands also meet at 
1609.29 cm−1 and 1664.08 cm−1 being attributed to (C =O). The band 
at 1565.98 cm−1 is related to the stretching vibrations of the amine 
group. Bending vibrations of methylene and methyl groups are 
located at 1236.03 cm−1 and 1258.99 cm−1
 
, respectively. Confirming 
the purity of the drug as per established standards. In the infrared 
spectra of the physical mixture of drug and polymers, the major 
peaks of aliskiren hemifumarate were at same wave numbers. 
However, some additional peaks were observed in the mixture, 
which could be due to the presence of polymer. 












































Fig. 1: FTIR spectra of aliskiren hemifumarate 
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Fig. 2: FTIR spectra of aliskiren hemifumarate with polymers 
 
Characterization of aliskiren hemifumrate transdermal patches 
for optimized formulations 
The average weights of the formulations prepared using glycerin as 
a plasticizer were ranged from 42.33-67.00 mg and propylene glycol 
as a plasticizer were ranged from 40.67-67.67 mg. The difference in 
weight depends on varying polymer concentration. 
Moisture content and moisture uptake studies indicated that the 
increase in the concentration of hydrophilic polymer was directly 
proportional to the increase in moisture content and moisture uptake of 
the patches. The moisture content of the prepared formulations was low, 
which could help the formulations remain stable and reduce brittleness 
during long-term storage. The moisture uptake of the formulations was 
also low, which could protect the formulations from microbial 
contamination and reduce bulkiness. The percentage moisture 
absorption varies from 1.76 to 10.73 for patches formulated using 
glycerin and 2.28 to 7.97 for propylene glycol patches. 
The percentage moisture loss from patches prepared using glycerin was 
range from 2.75 to 11.54 and 2.87 to 12.02 from propylene glycol. 
The water vapour transmission rate from patches prepared using 
glycerin was range from 0.25 to 0.92 and0.41 to 1.76.  
Thickness and folding of both patches were satisfactory. 
Good uniformity of drug content among the formulated patches. The 
acceptable quantity of medicament ranged from (100.20-101.05%). 
This result met the test content uniformly as per BP (85% to 115%). 
According to that, the drug was consistent throughout the patches. 
 
















Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
A 53.33 0.58 4.26 0.294 3.16 0.621 0.55 0.02 0.092 0.003 4.580 0.010 
B 58.33 0.58 5.16 1.063 3.85 0.237 0.54 0.30 0.066 0.005 4.553 0.015 
C 65.00 1.00 4.44 0.962 4.39 0.431 0.78 0.58 0.069 0.002 4.563 0.025 
D 42.33 1.53 4.79 1.086 2.79 0.715 0.53 0.17 0.043 0.002 4.547 0.023 
E 52.00 2.65 5.59 1.506 4.96 0.892 0.46 0.02 0.057 0.003 4.557 0.012 
F 61.67 1.15 5.66 1.069 5.60 0.463 0.34 0.01 0.079 0.006 4.567 0.015 
G 44.00 3.00 5.65 0.894 4.89 0.915 0.35 0.01 0.048 0.003 4.547 0.012 
H 52.00 1.00 6.04 0.344 5.56 0.475 0.46 0.02 0.052 0.004 4.570 0.010 
I 57.67 1.53 5.27 0.361 6.40 0.845 0.56 0.04 0.155 0.226 4.567 0.023 
J 49.00 2.00 6.14 0.290 5.08 0.751 0.48 0.04 0.061 0.002 4.570 0.020 
K 54.33 2.52 5.66 0.680 5.16 0.300 0.58 0.08 0.066 0.003 4.563 0.006 
L 63.00 2.65 7.32 1.189 6.55 0.221 0.39 0.13 0.072 0.003 4.557 0.021 
M 49.67 2.08 3.55 0.773 7.71 0.614 0.76 0.02 0.046 0.003 4.580 0.010 
N 57.00 2.00 5.51 1.129 8.46 0.278 0.75 0.08 0.052 0.002 4.557 0.012 
O 60.00 1.00 7.24 0.295 10.43 0.517 0.89 0.04 0.060 0.002 4.557 0.012 
P 47.67 1.53 7.47 1.055 7.98 0.235 0.73 0.02 0.035 0.003 4.570 0.020 
Q 51.33 2.08 8.66 0.669 9.59 0.597 0.87 0.07 0.041 0.002 4.567 0.015 
R 67.00 1.00 10.73 0.570 11.54 0.255 0.92 0.08 0.045 0.003 4.563 0.021 
S 52.33 1.53 2.65 0.315 3.15 0.245 0.34 0.05 0.040 0.002 4.567 0.015 
T 61.00 2.00 1.76 0.598 4.12 0.318 0.41 0.04 0.044 0.002 4.563 0.012 
U 65.33 1.53 3.49 1.072 5.08 0.372 0.59 0.04 0.050 0.002 4.557 0.015 
V 49.67 2.08 4.09 0.774 2.75 0.365 0.25 0.09 0.042 0.002 4.560 0.000 
W 54.33 2.31 4.46 0.730 4.14 0.238 0.49 0.05 0.050 0.002 4.563 0.021 
X 59.33 1.53 6.10 0.402 4.82 0.297 0.44 0.09 0.056 0.002 4.543 0.015 
(mean value±SD) (n=3);SD: Standard deviation 
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Table 3: Result showing effect of physicochemical properties of patches prepared using propylene glycol as plasticizer 













Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
PGA 53.67 0.58 4.43 0.09 2.87 0.94 0.54 0.03 0.09 0.00 4.51 0.02 
PGB 57.33 0.58 4.93 0.15 4.32 0.78 0.85 0.09 0.07 0.00 4.54 0.02 
PGC 64.67 0.58 5.25 0.25 4.02 0.34 1.49 0.64 0.07 0.00 4.52 0.03 
PGD 40.67 0.58 3.87 0.78 3.14 0.40 0.83 0.09 0.05 0.00 4.55 0.03 
PGE 53.67 1.53 6.22 0.44 4.90 0.78 0.91 0.31 0.06 0.00 4.55 0.04 
PGF 63.67 0.58 5.97 1.71 6.08 0.75 0.52 0.11 0.38 0.41 4.56 0.01 
PGG 44.67 2.08 5.25 1.04 4.53 0.99 0.41 0.02 0.05 0.00 4.52 0.02 
PGH 52.00 0.00 6.11 0.44 4.77 1.17 0.52 0.04 0.05 0.00 4.54 0.04 
PGI 57.67 0.58 4.83 0.81 7.11 0.98 0.64 0.03 0.06 0.00 4.57 0.02 
PGJ 51.00 1.00 7.20 0.21 5.22 0.89 0.57 0.10 0.06 0.00 4.55 0.02 
PGK 55.33 0.58 4.65 0.94 4.93 1.52 0.83 0.12 0.07 0.00 4.54 0.04 
PGL 65.00 1.00 7.97 0.27 6.97 0.58 0.54 0.07 0.08 0.00 4.54 0.03 
PGM 48.33 1.15 4.89 1.72 8.01 1.03 0.93 0.07 0.05 0.00 4.55 0.03 
PGN 57.33 1.15 5.93 0.63 8.81 0.21 1.08 0.25 0.05 0.00 4.54 0.04 
PGO 59.67 0.58 8.24 0.66 10.84 0.61 1.14 0.18 0.06 0.00 4.53 0.02 
PGP 47.67 1.15 7.49 1.01 8.52 0.99 1.76 0.75 0.03 0.00 4.54 0.03 
PGQ 51.67 0.58 9.21 0.44 11.08 0.59 0.95 0.05 0.04 0.00 4.53 0.05 
PGR 66.67 1.53 9.48 0.50 12.02 0.43 0.97 0.05 0.05 0.00 4.52 0.02 
PGS 53.67 0.58 2.69 0.76 3.39 0.41 0.62 0.17 0.04 0.00 4.55 0.02 
PGT 63.00 1.00 2.28 0.51 4.30 0.58 0.51 0.07 0.05 0.00 4.56 0.01 
PGU 67.67 1.53 4.28 0.71 5.16 0.29 0.83 0.14 0.05 0.00 4.52 0.03 
PGV 51.00 2.00 4.47 0.50 3.13 1.37 0.86 0.37 0.04 0.00 4.52 0.01 
PGW 54.67 1.53 4.96 0.39 4.16 1.25 0.86 0.18 0.05 0.00 4.53 0.04 
PGX 61.33 1.15 5.89 1.05 4.90 1.17 0.93 0.24 0.06 0.00 4.52 0.01 
(mean value±SD) (n=3);SD: Standard deviation 
 
In vitro permeation studies 
The cumulative percentage drug permeated by the individual path in 
the in vitro skin permeation studies were based on the mean amount 
of drug present in the respective patch. The in vitro drug release 
profile was studied using the best fit model from formulations 
prepared using varying concentration of polymer and different 
plasticizer. The percentage drug release was found best in 
formulation PGD with 43.75 % prepared with Methocel K 100 M 
using propylene glycol as a plasticizer. The plot of cumulative 
percent permeated for all the formulations was shown in the fig. 3 to 
6. All the formulations show the zero order release. 
  
 
Fig. 3: Plot of cumulative percent permeated versus time for formulations A-N 
 
 
Fig. 4: Plot of cumulative percent permeated versus time for formulations O-Z 
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Fig. 5: Plot of cumulative percent permeated versus time for formulations PGA-PGL 
 
 
Fig. 6: Plot of cumulative percent permeated versus time for formulations PGM-PGX 
 
Primary skin irritation studies 
The skin irritation test of the transdermal formulations PGD showed 
a skin irritation score (erythema and edema) of less than 2. The 
compounds producing scores of 2 or less are considered negative 
(no skin irritation). Hence, the developed transdermal formulations 
are free of skin irritation. 
DISCUSSION 
Transdermal route enhances the bioavailability of the drug by 
avoiding the first pass metabolism and increases the therapeutic 
efficacy of the drug by reaching into the systemic circulation. This is 
the most suitable system for a long-term treatment or for a multi-
dose treatment because transdermal patches are prepared for a long 
period of time in a single dose providing treatment from a day to 
even up to seven days. Synthetic and natural polymers were selected 
on the basis of their adhering property and nontoxicity. The result of 
the study showed good controlled release. The result from present 
study concluded that aliskiren in combination with Methocel K 
100M with an incorporation of propylene glycol produced a smooth, 
flexible and transparent film. FTIR studies showed characteristic 
peaks of aliskiren hemifumarate, confirming the purity of the drug. 
FT-IR spectral studies indicated there was no interaction between 
aliskiren hemifumarate and polymers used for the patches. 
The patches were prepared in varying composition of the polymers 
and evaluated it for physical parameters such as weight variation, 
thickness, drug content, water vapour transmission rate, % moisture 
loss and % moisture absorption. The drug content of transdermal drug 
delivery system (TDDS) patches ranged from 100.20-101.05%. Among 
all these formulations, the formulation PGD showed the maximum % 
drug cumulative release i.e. 43.75% up to 24 h of the study. 
CONCLUSION 
The primary objective of the study was to increase the 
bioavailability of the drug and secondary to study the effect of 
different polymers and plasticizer in the formulation. It can be 
concluded that the patches prepared using propylene glycol (PGD) 
shown better physicochemical properties and release profile over 
the patches prepared using glycerin. It can be used for an extended 
period without the risk of skin irritation. This will enhance the 
patient compliance throughout reduction of dosing administration. 
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